id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-297093-ld89vmct	Clark, Kristina E N	Safety of intravenous Anakinra in COVID-19 with evidence of hyperinflammation, a case series	2020-08-04		.txt	text/plain	3236	198	46	CONCLUSION: Intravenous anakinra is safe to use in patients with COVID-19 and evidence of supra-added bacterial infection. These patients all showed evidence of hyperinflammation with raised inflammatory markers, and CRP, and were given intravenous anakinra, with safe and successful use, suggesting the potential benefit from IL-1 blockade in this subgroup of patients with confirmed COVID-19. We present four cases of immunosuppressed patients, receiving beneficial effects from the use of intravenous anakinra to treat severe COVID-19 with hyperinflammation and concomitant bacterial infections. Our case series supports the hypothesis of IL-1 blockade as an important disease modifying treatment in those patients with severe late stage COVID-19, with evidence of cytokine storm. We believe that administering intravenous anakinra at the height of the cytokine storm has profound beneficial effects, both clinically and biochemically on patients with severe COVID-19 infection.	./cache/cord-297093-ld89vmct.txt	./txt/cord-297093-ld89vmct.txt